Navigation Links
Cardica's Cardiac Anastomosis Device Featured in Clinical Presentation on Robotic Cardiac Bypass Procedures
Date:9/9/2011

REDWOOD CITY, Calif., Sept. 9, 2011 /PRNewswire/ -- Cardica, Inc. (Nasdaq: CRDC) today reported that its C-Port® Flex-A® Anastomosis System will be featured in a clinical presentation to cardiothoracic surgeons this afternoon at the East Carolina Heart Institute-International Society for Minimally Invasive Cardiothoracic Surgery (ECHI-ISMICS) Summit in Greenville, North Carolina. The presentation, entitled "Robotic Coronary Revascularization: Connectors and Pearls," will be given by nationally-renowned cardiothoracic surgeon, Husam Balkhy, M.D., director of the Center for Robotic and Minimally Invasive Cardiac Surgery at The Wisconsin Heart Hospital, Milwaukee, Wisconsin.

"Dr. Balkhy has been using our anastomosis systems to attach the bypass graft vessels during minimally invasive cardiac surgery, for many years, with remarkable success," said Bernard A. Hausen, M.D., Ph.D., president and chief executive officer of Cardica, Inc. "This presentation offers other cardiothoracic surgeons the opportunity to see first-hand the difference between a connector bypass procedure using our automated anastomosis device compared to hand-sewing the anastomosis."

The presentation details how Dr. Balkhy uses Cardica's C-Port systems to perform a connector procedure, including selection of graft vessels, a description of the features and benefits of the C-Port system, and the mechanics of deployment during connector procedures on a beating heart in the closed chest setting, also known as a totally endoscopic coronary artery bypass (TECAB) procedure. In addition, Dr. Balkhy's use of the C-Port systems is described in the current peer-reviewed issue of The Annals of Thoracic Surgery in an article entitled "Integrating Coronary Anastomotic Connectors and Robotics Toward a Totally Endoscopic Beating Heart Approach: Review of 120 Cases." Dr. Balkhy is a recognized expert in the field of minimally invasive and robotic cardiothoracic surgery and has pioneered the connector procedure. He has trained physicians around the world on his technique using Cardica's C-Port Flex-A System.  

About Cardica

Cardica designs and manufactures proprietary stapling and anastomotic devices for cardiac and laparoscopic surgical procedures. Cardica's technology portfolio is intended to minimize operating time and enable minimally-invasive and robot-assisted surgeries. Cardica manufactures and markets its automated anastomosis systems, the C-Port® Distal Anastomosis Systems and PAS-Port® Proximal Anastomosis System, for coronary artery bypass graft (CABG) surgery and has shipped over 36,000 units throughout the world. In addition, Cardica is developing the Cardica MicroCutter XPRESS™ 30, a true multi-fire laparoscopic stapling device designed to be used in a variety of procedures, including bariatric, colorectal, thoracic and general surgery. The Cardica MicroCutter products require 510(k) review and are not yet commercially available in the U.S.

Forward-Looking Statements

This press release contains "forward-looking" statements, including all statements regarding the performance of the C-Port Systems during robotic cardiac bypass procedures. Any statements contained in this press release that are not historical facts may be deemed to be forward-looking statements. The words "offers," "intended" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause Cardica's results to differ materially from those indicated by these forward-looking statements, including that Cardica's current and any future products may never gain any significant degree of market acceptance; that any future Cardica products face development, regulatory, reimbursement and manufacturing risks; that Cardica's intellectual property rights may not provide adequate protection; that Cardica's sales, marketing and distribution strategy and capabilities may not be sufficient or successful; and that general business and economic conditions may impair Cardica's ability to market and develop products, as well as other risks detailed from time to time in Cardica's reports filed with the U.S. Securities and Exchange Commission, including its Quarterly Report filed on for 10-Q. Cardica expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein. You are encouraged to read Cardica's reports filed with the U.S. Securities and Exchange Commission, available at www.sec.gov.


'/>"/>
SOURCE Cardica, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NIH-Funded Study Demonstrates That Patients Receiving New CPR Devices (ResQPOD® and ResQPump™) and Cooling Have Improved Long-Term Brain Function Following Cardiac Arrest
2. Philips Unveils a Vision for the Future of Cardiac Care at ESC 2011
3. India Cardiac Catheters and Guidewires - Market Trends Till 2016
4. China Cardiac Catheters and Guidewires - Market Trends Till 2016
5. JHP Pharmaceuticals to Produce Clinical Batches of Innovative Cardiac Drug
6. Cardiac Science Expands Device Connectivity Solutions
7. OrbusNeichs Genous™ Stent Enables Early and Safe Discontinuation of Dual Antiplatelet Therapy in High-Risk Patients Requiring Nondeferrable, Non-Cardiac Surgery
8. Cardiac Science Gains Japanese Regulatory Approval for Powerheart AED
9. Reportlinker Adds US Cardiac Assist Devices -- Market Trend Till 2016
10. Mitsubishi Chemical Medience Corporation Receives 510(k) Clearance for PATHFAST® cTnI-II (cardiac Troponin I) Test in U.S.
11. Reportlinker Adds European Markets for Cardiac Surgery Devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2017)... 15, 2017 Enterin Inc., a privately-held CNS pharmaceutical ... novel compounds to treat Parkinson,s disease (PD), has enrolled the ... Phase 1/2a randomized, controlled, multicenter study involving patients with PD ... 50 patients over a 9-to-12-month period. The first stage is ... with PD. Participating sites include Denver , ...
(Date:5/10/2017)... -- The Corporate Whistleblower Center says, "We are urging ... to call us anytime at 866-714-6466 if they possess ... a substantial scheme to overbill Medicare. We are ... of a medical equipment company if their employer ... practice groups with extra generous incentives to use, or ...
(Date:5/9/2017)... 2017  Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug ... Property Office has granted Oramed a patent titled, ... The patent covers Oramed,s invention of an oral ... an incretin hormone that stimulates the secretion of ...
Breaking Medicine Technology:
(Date:5/23/2017)... ... May 23, 2017 , ... Axiad IDS , a leading ... Applications magazine has named the company a “Top 25 Cybersecurity Companies 2017.” ... to help organizations simply and proactively address potential cybersecurity threats before they happen. ...
(Date:5/23/2017)... , ... May 23, 2017 , ... ... technology and a 2017 Best in KLAS category winner, has named Daniel P. ... to extend and enhance its technology platform and product offerings,” says Justin Neece, ...
(Date:5/23/2017)... ... May 23, 2017 , ... Drs. ... on peri-implantitis in Las Vegas, NV, and the importance of treating ... disease consultation and leading care for peri-implantitis, with or without a referral. As ...
(Date:5/23/2017)... ... May 23, 2017 , ... New patients with symptoms of gum disease ... receive laser gum disease treatments from the doctors at Art of Dentistry, without first ... awareness of the importance of receiving qualified treatment in order to avoid systemic health ...
(Date:5/22/2017)... ... May 22, 2017 , ... Patients who avoid necessary dental and ... dentistry in Mt. Kisco, NY from Advanced Endodontics of Westchester. This highly-trained team of ... treatments. One or more sedation methods may be recommended based on the severity of ...
Breaking Medicine News(10 mins):